The "Tenderness and Rage" exhibition at the Wellcome Collection in London provides a historical overview of AIDS activism, focusing on the efforts to improve the rights and dignity of those living with the disease. The exhibition also raises important questions about the role of pharmaceutical companies, institutional investments, and the complexities of providing affordable treatments during a public health crisis.

The exhibition documents the activism of various groups, including the UK Aids Coalition, whose “die-in” protest in Trafalgar Square symbolized the urgency of the situation. The exhibition also showcases the efforts of support services, such as the Landmark drop-in center in Tulse Hill, which provided a safe space for individuals affected by HIV/AIDS.

One of the key issues highlighted is the controversy surrounding the pricing of AZT, the first effective HIV drug. Act UP activists campaigned against the high cost of the medication, which was produced by a pharmaceutical company in which the Wellcome Trust held a substantial stake. This situation raises questions about the ethical responsibilities of institutions with significant investments in pharmaceutical companies and their role in ensuring access to life-saving treatments.

The activism surrounding AZT's pricing reflects a broader debate about intellectual property rights, market forces, and the balance between incentivizing pharmaceutical innovation and ensuring affordable access to medications. The exhibition invites viewers to consider the complexities of this issue and the potential trade-offs involved.

While the exhibition highlights the concerns raised by activists, it also indirectly underscores the significant investment and research required to develop effective treatments for diseases like HIV/AIDS. Pharmaceutical companies play a crucial role in this process, and their ability to recoup investments through drug pricing is essential for continued innovation.

The exhibition also raises questions about the appropriate role of government regulation in drug pricing and the potential impact of such regulations on pharmaceutical innovation and investment. Striking a balance between affordability and innovation remains a significant challenge for policymakers.

Furthermore, the exhibition indirectly highlights the importance of personal responsibility and informed decision-making in preventing the spread of HIV/AIDS. While activism and access to treatment are essential, individuals also have a responsibility to protect themselves and others through safe practices.